Reflect Scientific, Inc. (RSCF)
USD 0.04
(-3.26%)
USD 0.04
(-3.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.06 Million USD | -62.96% |
| 2022 | 1.12 Million USD | 2.38% |
| 2021 | 1.1 Million USD | 3.04% |
| 2020 | 1.07 Million USD | -9.79% |
| 2019 | 1.18 Million USD | -9.68% |
| 2018 | 1.31 Million USD | 23.69% |
| 2017 | 1.06 Million USD | -0.2% |
| 2016 | 1.06 Million USD | -2.39% |
| 2015 | 1.09 Million USD | -30.48% |
| 2014 | 1.56 Million USD | 15.95% |
| 2013 | 1.35 Million USD | 20.37% |
| 2012 | 1.12 Million USD | -29.63% |
| 2011 | 1.59 Million USD | 35.46% |
| 2010 | 1.17 Million USD | -74.84% |
| 2009 | 4.68 Million USD | -9.21% |
| 2008 | 5.16 Million USD | -41.33% |
| 2007 | 8.79 Million USD | 303.27% |
| 2006 | 2.18 Million USD | 155.78% |
| 2005 | 852.86 Thousand USD | 22.31% |
| 2004 | 697.31 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 112.16 Thousand USD | -19.7% |
| 2024 Q1 | 139.67 Thousand USD | 11.77% |
| 2023 Q3 | 249.09 Thousand USD | 3.22% |
| 2023 FY | 418.18 Thousand USD | -62.96% |
| 2023 Q4 | 124.97 Thousand USD | -49.83% |
| 2023 Q2 | 241.31 Thousand USD | -12.36% |
| 2023 Q1 | 275.33 Thousand USD | 1.84% |
| 2022 Q1 | 142.5 Thousand USD | -30.71% |
| 2022 FY | 1.12 Million USD | 2.38% |
| 2022 Q2 | 281.66 Thousand USD | 97.66% |
| 2022 Q3 | 264.24 Thousand USD | -6.18% |
| 2022 Q4 | 270.35 Thousand USD | 2.31% |
| 2021 Q4 | 205.65 Thousand USD | -34.49% |
| 2021 Q3 | 313.91 Thousand USD | 4.23% |
| 2021 Q2 | 301.17 Thousand USD | 107.05% |
| 2021 Q1 | 145.46 Thousand USD | -10.89% |
| 2021 FY | 1.1 Million USD | 3.04% |
| 2020 Q3 | 153.78 Thousand USD | -62.1% |
| 2020 Q1 | 347.58 Thousand USD | -28.83% |
| 2020 FY | 1.07 Million USD | -9.79% |
| 2020 Q2 | 405.81 Thousand USD | 16.75% |
| 2020 Q4 | 163.24 Thousand USD | 6.15% |
| 2019 Q2 | 198.5 Thousand USD | -16.21% |
| 2019 Q3 | 261.82 Thousand USD | 31.9% |
| 2019 Q4 | 488.4 Thousand USD | 86.54% |
| 2019 FY | 1.18 Million USD | -9.68% |
| 2019 Q1 | 236.9 Thousand USD | -42.78% |
| 2018 FY | 1.31 Million USD | 23.69% |
| 2018 Q4 | 414.04 Thousand USD | 65.56% |
| 2018 Q3 | 250.09 Thousand USD | -41.96% |
| 2018 Q2 | 430.87 Thousand USD | 97.97% |
| 2018 Q1 | 217.65 Thousand USD | -57.99% |
| 2017 Q1 | 168.27 Thousand USD | -62.05% |
| 2017 FY | 1.06 Million USD | -0.2% |
| 2017 Q4 | 518.05 Thousand USD | 184.37% |
| 2017 Q3 | 182.17 Thousand USD | 9.67% |
| 2017 Q2 | 166.1 Thousand USD | -1.29% |
| 2016 FY | 1.06 Million USD | -2.39% |
| 2016 Q1 | 230.75 Thousand USD | -54.89% |
| 2016 Q4 | 443.39 Thousand USD | 133.75% |
| 2016 Q3 | 189.68 Thousand USD | -5.3% |
| 2016 Q2 | 200.31 Thousand USD | -13.19% |
| 2015 Q1 | 193.62 Thousand USD | -80.21% |
| 2015 FY | 1.09 Million USD | -30.48% |
| 2015 Q4 | 511.49 Thousand USD | 161.69% |
| 2015 Q3 | 195.46 Thousand USD | 3.1% |
| 2015 Q2 | 189.57 Thousand USD | -2.09% |
| 2014 Q3 | 207.91 Thousand USD | 3.66% |
| 2014 FY | 1.56 Million USD | 15.95% |
| 2014 Q4 | 978.25 Thousand USD | 370.5% |
| 2014 Q2 | 200.57 Thousand USD | 10.52% |
| 2014 Q1 | 181.48 Thousand USD | -73.57% |
| 2013 Q2 | 229.63 Thousand USD | 7.47% |
| 2013 Q4 | 686.52 Thousand USD | 208.38% |
| 2013 Q1 | 213.68 Thousand USD | -26.96% |
| 2013 Q3 | 222.62 Thousand USD | -3.05% |
| 2013 FY | 1.35 Million USD | 20.37% |
| 2012 Q3 | 278.66 Thousand USD | 1.9% |
| 2012 Q4 | 292.55 Thousand USD | 4.98% |
| 2012 FY | 1.12 Million USD | -29.63% |
| 2012 Q1 | 278.92 Thousand USD | -37.48% |
| 2012 Q2 | 273.47 Thousand USD | -1.95% |
| 2011 Q2 | 490.73 Thousand USD | 40.07% |
| 2011 Q4 | 446.11 Thousand USD | 44.09% |
| 2011 Q3 | 309.6 Thousand USD | -36.91% |
| 2011 Q1 | 350.35 Thousand USD | 15.33% |
| 2011 FY | 1.59 Million USD | 35.46% |
| 2010 Q1 | 302.13 Thousand USD | -77.25% |
| 2010 FY | 1.17 Million USD | -74.84% |
| 2010 Q4 | 303.77 Thousand USD | 8.67% |
| 2010 Q3 | 279.55 Thousand USD | -4.71% |
| 2010 Q2 | 293.37 Thousand USD | -2.9% |
| 2009 Q3 | 1.02 Million USD | -9.96% |
| 2009 FY | 4.68 Million USD | -9.21% |
| 2009 Q1 | 1.19 Million USD | 0.3% |
| 2009 Q2 | 1.14 Million USD | -4.14% |
| 2009 Q4 | 1.32 Million USD | 29.32% |
| 2008 Q3 | 1.42 Million USD | 2.82% |
| 2008 Q2 | 1.38 Million USD | 19.94% |
| 2008 Q4 | 1.18 Million USD | -16.91% |
| 2008 Q1 | 1.15 Million USD | -74.54% |
| 2008 FY | 5.16 Million USD | -41.33% |
| 2007 Q4 | 4.54 Million USD | 290.32% |
| 2007 FY | 8.79 Million USD | 303.27% |
| 2007 Q1 | 808.38 Thousand USD | 44.34% |
| 2007 Q2 | 2.27 Million USD | 181.63% |
| 2007 Q3 | 1.16 Million USD | -48.83% |
| 2006 Q3 | 1 Million USD | 144.36% |
| 2006 Q1 | 226.84 Thousand USD | 14.2% |
| 2006 Q4 | 560.06 Thousand USD | -44.54% |
| 2006 FY | 2.18 Million USD | 155.78% |
| 2006 Q2 | 413.25 Thousand USD | 82.17% |
| 2005 Q4 | 198.63 Thousand USD | 4.25% |
| 2005 FY | 852.86 Thousand USD | 22.31% |
| 2005 Q3 | 190.53 Thousand USD | -27.27% |
| 2005 Q1 | 201.73 Thousand USD | 0.0% |
| 2005 Q2 | 261.96 Thousand USD | 29.85% |
| 2004 FY | 697.31 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | 62.851% |
| Ansell Limited | 495.5 Million USD | 99.785% |
| Ansell Limited | 495.5 Million USD | 99.785% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | 98.715% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | 38.541% |
| Psykey, Inc. | 1.21 Million USD | 12.343% |
| ConvaTec Group Plc | 910.31 Million USD | 99.883% |
| ConvaTec Group Plc | 872.5 Million USD | 99.878% |
| Encision Inc. | 3.77 Million USD | 71.836% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -650.082% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -867.606% |
| Innovative MedTech Inc. | 6.09 Million USD | 82.559% |
| LifePoint, Inc. | 7.42 Million USD | 85.672% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | 83.246% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | -24.409% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 726.13 Thousand USD | -46.488% |
| SmileDirectClub, Inc. | 517 Million USD | 99.794% |
| Sector 10, Inc. | 39.84 Thousand USD | -2569.659% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 99.984% |
| SheerVision, Inc. | 2.33 Million USD | 54.38% |
| United Health Products, Inc. | 2.42 Million USD | 56.164% |
| Vasamed, Inc. | 4.67 Million USD | 77.237% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | 58.479% |
| Yubo International Biotech Limited | 1.25 Million USD | 15.437% |